- OVERVIEW The overall goal of the proposed renewal of the Rush Alzheimer?s Disease Core Center (Rush ADCC) is to continue to support the performance of cutting edge and innovative research on the etiology, pathogenesis, diagnosis, treatment, and prevention of MCI, AD, and other common dementias, by providing researchers with a stimulating multi-disciplinary environment, and unique and highly valued clinical and post-mortem data, and ante- and post-mortem biologic specimens. The Rush ADCC has been in continuous operation since 1991. It has eight Cores carefully designed to support a variety of timely and important areas of research including studies: 1) of the transition from normal aging to MCI and to the earliest stages of dementia with substantial participation by racial and ethnic minorities, 2) linking risk factors to normal aging, incident MCI and incident AD, and to post-mortem indices of AD and mixed pathologies, 3) that incorporate contemporary high throughput biochemical and molecular data into clinical-pathologic cohort studies, and 4) that link neuroimaging and biofluid biomarkers to contemporary biochemical and molecular data, 5) that support drug discovery pipelines, and 6) that support studies of impaired motor function. The Administrative Core will provide scientific leadership to the ADCC as a whole. The Clinical Core will collect UDS and additional data on Blacks without dementia and work to obtain brain autopsy. The Religious Orders Study (ROS) Core will follow older members of Catholic religious communities who have agreed to annual evaluation and brain donation at death. The Latino Core will collect the same data as in ROS on older Latinos without dementia and work to obtain brain autopsy. The Neuropathology Core will process, store, evaluate and distribute biospecimens obtained by the Clinical, ROS, and Latino Cores. The Outreach and Recruitment Core will provide a wide range of educational programs to support outreach and recruitment of racial and ethnic minorities into the Clinical and Latino Cores, and other NIA funded initiatives. The Data Management and Statistical Core will continue to provide the infrastructure that allows all other Cores to be maximally successful and impactful, and will provide statistical support to users of ADCC resources especially junior investigators and trainees. The new Research and Education Component will provide a structured program of mentorship across the ADCC, Rush University of the Rush ADCC strategic partners.

Public Health Relevance

- OVERVIEW The prevention of cognitive decline, MCI and dementia is a major public health priority. The proposed continuation of the Rush Alzheimer?s Disease Core Center will generate resources that are being used to support a deeper understanding of the pathogenesis of MCI and dementia, and to identify novel therapeutic targets for its treatment and prevention.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG010161-30
Application #
9977065
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Elliott, Cerise
Project Start
1997-08-15
Project End
2021-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
30
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Rush University Medical Center
Department
Neurosciences
Type
Schools of Medicine
DUNS #
068610245
City
Chicago
State
IL
Country
United States
Zip Code
60612
McAninch, Elizabeth A; Rajan, Kumar B; Evans, Denis A et al. (2018) A Common DIO2 Polymorphism and Alzheimer Disease Dementia in African and European Americans. J Clin Endocrinol Metab 103:1818-1826
Power, Melinda C; Mormino, Elizabeth; Soldan, Anja et al. (2018) Combined neuropathological pathways account for age-related risk of dementia. Ann Neurol 84:10-22
Samieri, Cécilia; Morris, Martha-Clare; Bennett, David A et al. (2018) Fish Intake, Genetic Predisposition to Alzheimer Disease, and Decline in Global Cognition and Memory in 5 Cohorts of Older Persons. Am J Epidemiol 187:933-940
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Bennett, David A (2018) Lack of Benefit With Idalopirdine for Alzheimer Disease: Another Therapeutic Failure in a Complex Disease Process. JAMA 319:123-125
Kaur, Antarpreet; Edland, Steven D; Peavy, Guerry M (2018) The MoCA-Memory Index Score: An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 32:120-124
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17
Lee, Catherine; Betensky, Rebecca A; Alzheimer's Disease Neuroimaging Initiative (2018) Time-to-event data with time-varying biomarkers measured only at study entry, with applications to Alzheimer's disease. Stat Med 37:914-932
Lamar, Melissa; Yu, Lei; Rubin, Leah H et al. (2018) APOE genotypes as a risk factor for age-dependent accumulation of cerebrovascular disease in older adults. Alzheimers Dement :

Showing the most recent 10 out of 786 publications